@article{fdi:010085949,
  title = {{O}utcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with {HIV} in {E}urope and {T}hailand},
  author = {{L}yons, {A}. and {T}hompson, {L}. and {C}happell, {E}. and {E}ne, {L}. and {G}alli, {L}. and {G}oetghebuer, {T}. and {J}ourdain, {G}onzague and {N}oguera-{J}ulian, {A}. and {K}ahlert, {C}. {R}. and {K}onigs, {C}. and {K}osalaraksa, {P}. and {L}umbiganon, {P}. and {M}arczynska, {M}. and {M}arques, {L}. and {N}avarro, {M}. and {N}aver, {L}. and {O}khonskaia, {L}. and {P}rata, {F}. and {P}uthanakit, {T}. and {R}amos, {J}. {T}. and {S}amarina, {A}. and {T}horne, {C}. and {V}oronin, {E}. and {T}urkova, {A}. and {G}iaquinto, {C}. and {J}udd, {A}. and {C}ollins, {I}. {J}. and {E}uropean {P}regnancy and {P}aediatric {I}nfections {C}ohort {C}ollaboration ({EPPICC}) {S}tudy {G}roup},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {E}travirine ({ETR}) is approved as a component of second or third-line antiretroviral treatment ({ART}) for children living with {HIV}. {W}e assessed the outcomes of {ETR}-based {ART} in children in routine care in {E}urope and {T}hailand. {M}ethods: {D}ata on children aged <18 years at {ETR} start were pooled from 17 observational cohorts. {C}haracteristics at {ETR} start, immunological and virological outcomes at 12 months, discontinuations, adverse events ({AE}s) and serious adverse events ({SAE}s) were described. {F}ollow-up was censored at {ETR} discontinuation, death or last visit. {R}esults: 177 children ever received {ETR}. {A}t {ETR} start, median [{IQR}] age was 15 [12,16] years, {CD}4 count 480 [287, 713] cells/mm(3), 70% had exposure to >= 3 {ART} classes and 20% had viral load ({VL}) <50 copies/m{L}. 95% received {ETR} in combination with >= 1 potent drug class, mostly protease inhibitor-based regimens. {M}edian time on {ETR} was 24 [7, 48] months. {A}mongst those on {ETR} at 12 months (n=141), 69% had {VL}<50 copies/m{L}. {M}edian {CD}4 increase since {ETR} start (n=83) was 147 [16, 267] cells/mm(3). {O}verall, 81 (46%) discontinued {ETR} by last follow-up. {M}edian time to discontinuation was 23 [8, 47] months. {C}ommon reasons for discontinuation were treatment simplification (19%), treatment failure (16%) and toxicity (12%). {E}ight children (5%) had {AE}s causally associated with {ETR}, all dermatological/hypersensitivity reactions. {T}wo were {SAE}s, both {S}tevens-{J}ohnson {S}yndrome in children on regimens containing {ETR} and darunavir and were causally related to either drugs; both resolved following {ART} discontinuation. {C}onclusion: {C}hildren receiving {ETR} were predominantly highly treatment-experienced, over two-thirds were virally suppressed at 12 months.},
  keywords = {{EUROPE} ; {THAILANDE}},
  booktitle = {},
  journal = {{A}ntiviral {T}herapy},
  volume = {27},
  numero = {3},
  pages = {7},
  ISSN = {1359-6535},
  year = {2022},
  DOI = {10.1177/13596535221092182},
  URL = {https://www.documentation.ird.fr/hor/fdi:010085949},
}